A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a ...

The RAS(ON) inhibitor shrunk tumors in around 60 percent of patients with KRAS G12D mutations, according to a study presented at AACR's annual meeting.

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, ...

Explore the evolving landscape of non-small cell lung cancer (NSCLC) treatment, where targeted therapies address ten actionable genomic alterations (AGAs). Discover innovations in EGFR mutations, ...

Cindy was a healthy, 35-year-old woman with no symptoms of cancer when she joined the American Lung Association’s Lung Health Cohort Study.

Not enough Brits are seeking medical help after noticing possible signs of cancer and below people who have been diagnosed ...

Northwestern Medicine scientists have uncovered how a testis-specific protein contributes to tumor growth and progression in ...

Medicine is capable of detecting cancer and identifying how cancers might resist treatment. Here are four things to know about the test: Read the full study here.

Clinical trials improve care and access to novel treatments for advanced gastrointestinal cancers, says Dr. Michael Pishvaian ...

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...